EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis On the final day of EULAR, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of PMR, GCA, and TAK. There were 5 overarching principles and 12 https://t.co/kpykylEbsr

The North American Expert Consensus on ASCVD Screening in Lupus Nephritis Drs. Sheila Reyes and Shivani Garg discuss abstract OP094, presented in London at the EULAR 2026 Congress https://t.co/Vm2QFlO3fL https://t.co/4Xp9tkubLh

Usual testing for SSA (Ro) pos. in Sjogrens identifies both Ro52 + Ro60 Abs, found in 70% of SjD. Pts who are double pos (Ro52+Ro60) have more severe dz, more Bcell activity. Ro60+ have milder dz; Recent report shows SjD pts have Ro60-specific CD4 T cells, activating Bcells https://t.co/SqoLICHOkS

Prevalence of GI involvement in dermatomyositis (DM) was assessed in 2 cohorts (n = 167). Severe GI involvement seen in 18% NXP2+ & 6% MDA5+; more common w/ NXP2 than other DM (HR 8.85). NXP2 w/ severe GI dz were younger, facial edema @dx w/ both skin & muscle dz activity. https://t.co/5kNvAkTLc0

Genicular artery embolization (GAE) in knee OA? Multiple open label studies & metanalyses suggest a clear pain benefit; BUT 3 sham-controlled RCTs have not demonstrated a statistically significant benefit over placebo. GAE is not addressed by ACR or EULAR guidelines. https://t.co/4JPm7gzCue

From Cytokine Endotypes to Clinical Reality in Still’s Disease Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy. https://t.co/FrghBJdlXj https://t.co/CbHYDKbnK9

Increased VTE Risk with Baricitinib The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026 (LB0009). This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — https://t.co/5cQ829x77u

Induction of Cure in Early Arthritis treated early DMARD-naïve Undiff. Arthritis (≥2 joints) w/ NSAIDs (29), MTX 15-25/wk (28), or baricitinib 4 mg/d (28) x 3 mos. Entry DAS ~ 2.4 w/ 2-3 SJC, <17%CCP+. @3 mos Bari > NSAID (DAS−0.52;p=0.01) = MTX (−0.39, p=0.09).@1yr MTX DAS https://t.co/1kKjginhKM

20% sample of elder RA Medicare pts (2009-2022) on TNFi who either stopped or tapered TNFi found 38% sustained de-escalation, while 62% re-escalated within a medianof 164. Re-escalation was more likely in Blacks, Hispanic/other, with a lower comorbidity burden. https://t.co/rEB3VdOii2

US telehealth utilization rose 10.1% in 1st quarter of 2026 (5% to 5.51% medical claims). Most use in mental health conditions (52%) w/ joint/soft tissue dz at 3% overall, higher in west & NE states. 57% for outpt visits, only 7.7% for new visits. 35% for psychotherapy services. https://t.co/L8c7p3iQPL

From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg

Nature has published that Hyperglycosylation is a metabolic driver of Alzheimer’s Dz (AD) & Glucosamine (GS; taken by ~7% over 70yrs) & GS may increase hyperglycosylation. A retrosp EHR study of AD pts shows glucosamine use assoc w/ accelerated AD progression & worse survival https://t.co/bv6H9h6gAv